BRAF and plasma cell myeloma: Similarly, TP53 (67%), CDKN2C (33%), PRKD2 (18%), FAM46C (15%), and BRAF (15%) mutation rates displayed a dramatically increased frequency in HMCLs compared with those in primary myeloma cells, either in DMM or RMM [2, 20–24] (Fig. 2).